# Secretome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/secretome-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.secretometherapeutics.com/
- Total disclosed funding: $30M
- Latest round: Series A (May 27, 2026)
- Investors on record: 1

## About

Secretome Therapeutics, based in the USA, develops innovative therapies from neonatal cardiac progenitor cells (nCPCs) to address unmet needs in cardiovascular disease treatment.Secretome Therapeutics focuses on creating therapies from neonatal cardiac progenitor cells, emphasizing treatments for heart failure and dilated cardiomyopathy. Founded in 2018 in Baltimore, US, the company has made three deals, with its latest funding round raising USD 20.4 mn on November 25, 2024. The founder's history is not publicly available.Secretome Therapeutics specializes in developing innovative therapies derived from neonatal cardiac progenitor cells (nCPCs) to address significant unmet medical needs in the treatment of cardiovascular diseases. Their lead products, STM-01 and its secretome, STM-21, target heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM). The therapies are aimed at healthcare professionals and clinical researchers, with ongoing clinical trials to enroll diverse patient demographics.Secretome Therapeutics generates revenue primarily through the development and commercialization of investigational medicines via clinical trials and partnerships with healthcare organizations. Collaborations with clinical research institutions enable the assessment of product efficacy and safety. Specific pricing plans for their therapies have not been disclosed, but the company focuses on B2B relationships with research entities and healthcare providers, with potential revenue streams from successful trial outcomes leading to licensing agreements or partnerships for STM-01 and STM-21. In May 2026, Secretome Therapeutics raised USD 30 million in series A funding from new investor RA Capital Management. The company will use the May 2026 funding to accelerate development of STM-01 for Duchenne-associated cardiomyopathy.

## Funding rounds

- Series A, May 27, 2026, $30M — RA Capital Management

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A